aTyr Pharma, Inc. (NASDAQ: ATYR) Securities Fraud Class Action

LEAD PLAINTIFF DEADLINE IS DECEMBER 8, 2025.

If you have suffered losses and would like to discuss your rights, please fill out this form or you may contact Jonathan Naji, Esq. at (484) 270-1453 or via e-mail at [email protected].

Case Background:
Class action lawsuits have been filed on behalf of those who purchased or otherwise acquired aTyr Pharma, Inc. (“aTyr”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).

aTyr is a clinical stage biotechnology company focused on innovative therapeutic interventions. Since late-2022, aTyr has been conducting a Phase 3 study to evaluate the safety and efficacy of intravenous Efzofitimod (“EFZO-FIT”) in patients with pulmonary sarcoidosis (the “EFZO-FIT Study”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company’s business, operations, and prospects.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) the design of the EFZO-FIT Study would not permit the company to fully remove steroids from each patient’s treatment plans as claimed by Defendants; (2) there may be external factors that permit patients to completely remove oral corticosteroids from their treatment plans, undercutting the efficacy of Efzofitimod and the undermining the results of the EFZO-FIT Study; and (3) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

What is a Lead Plaintiff?

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Filling out the online form above or communicating with any counsel is not necessary to participate or share in any recovery achieved in this case.  Any member of the purported class may move the court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.